advertisement
Abstract #47925 Published in IGR 13-4
From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month, multicenter, open-label tolerability switch study
Rossi GCM; Pasinetti GM; Sandolo F; Bordin M; Bianchi PEExpert Opinion in Pharmacotherapy 2011; 12: 2425-2431
Purpose: To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Methods: Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median interquartile range (IQR) IOP was 16 (IQR 15 18) mmHg at baseline and 16 (15 17) mmHg and 6 months. TF-BUT significantly improved (p < 0.0001); the regression analysis found a negative association between TF-BUT changes and age at baseline and at month 6 (r = -0.32; p = 0.0082 and r = -0.31; p = 0.0085). Patients with no corneal fluorescein staining statistically increased after substitution (p = 0.04). Quality of life as examined by the GSS symptoms (SYMP) score statistically improved (p < 0.0001), revealing an association between GSS SYMP score and age [coefficient -0.67, 95% confidence interval (CI) -1.13 to -0.21, p = 0.0005), superficial keratitis (coefficient -8.26, 95% CI -15.73 to -0.80, p = 0.031) and TF-BUT (coefficient 4.94, 95% CI 1.71 to 8.17, p = 0.003). Conclusion: Brinzolamide/timolol FC is associated with reduced topical discomfort and improved signs of ocular surface disease. The good tolerability and comfort of this FC might contribute to good patient adherence. (copyright) 2011 Informa UK, Ltd.
G.C.M. Rossi. University Eye Clinic of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Piazzale Golgi 19, 27100 Pavia, Italy. Email: gemma.rossi.md@gmail.com
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
